Yue Zhao1, Yakun Gao2, Xiaodong Xu3, Jiwu Zhou4, He Wang5. 1. Department II of Radiotherapy, Cangzhou Central Hospital, No.16 Xinhua West Road, Cangzhou, 061110, Hebei, China. drzhaoyue2019@163.com. 2. Department of Ultrasound, Cangzhou Central Hospital, Cangzhou, 061110, Hebei, China. 3. School of Clinical Medicine, Cangzhou Medical College, Cangzhou, 061001, Hebei, China. 4. Department II of Radiotherapy, Cangzhou Central Hospital, No.16 Xinhua West Road, Cangzhou, 061110, Hebei, China. 5. Office of Educational Administration, Hebei Medical University, No.361 Zhongshan East Road, Shijiazhuang, 050017, Hebei, China. wanghe@hebmu.edu.cn.
Abstract
BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequently diagnosed histological subtype of lung cancer. Our purpose was to explore molecular subtypes and core genes for LUAD using multi-omics analysis. METHODS: Methylation, transcriptome, copy number variation (CNV), mutations and clinical feature information concerning LUAD were retrieved from The Cancer Genome Atlas Database (TCGA). Molecular subtypes were conducted via the "iClusterPlus" package in R, followed by Kaplan-Meier survival analysis. Correlation between iCluster subtypes and immune cells was analyzed. Core genes were screened out by integration of methylation, CNV and gene expression, which were externally validated by independent datasets. RESULTS: Two iCluster subtypes were conducted for LUAD. Patients in imprinting centre 1 (iC1) subtype had a poorer prognosis than those in iC2 subtype. Furthermore, iC2 subtype had a higher level of B cell infiltration than iC1 subtype. Two core genes including CNTN4 and RFTN1 were screened out, both of which had higher expression levels in iC2 subtype than iC1 subtype. There were distinct differences in CNV and methylation of them between two subtypes. After validation, low expression of CNTN4 and RFTN1 predicted poorer clinical outcomes for LUAD patients. CONCLUSION: Our findings comprehensively analyzed genomics, epigenomics, and transcriptomics of LUAD, offering novel underlying molecular mechanisms for LUAD. Two multi-omics-based core genes (CNTN4 and RFTN1) could become potential therapeutic targets for LUAD.
BACKGROUND:Lung adenocarcinoma (LUAD) is the most frequently diagnosed histological subtype of lung cancer. Our purpose was to explore molecular subtypes and core genes for LUAD using multi-omics analysis. METHODS: Methylation, transcriptome, copy number variation (CNV), mutations and clinical feature information concerning LUAD were retrieved from The Cancer Genome Atlas Database (TCGA). Molecular subtypes were conducted via the "iClusterPlus" package in R, followed by Kaplan-Meier survival analysis. Correlation between iCluster subtypes and immune cells was analyzed. Core genes were screened out by integration of methylation, CNV and gene expression, which were externally validated by independent datasets. RESULTS: Two iCluster subtypes were conducted for LUAD. Patients in imprinting centre 1 (iC1) subtype had a poorer prognosis than those in iC2 subtype. Furthermore, iC2 subtype had a higher level of B cell infiltration than iC1 subtype. Two core genes including CNTN4 and RFTN1 were screened out, both of which had higher expression levels in iC2 subtype than iC1 subtype. There were distinct differences in CNV and methylation of them between two subtypes. After validation, low expression of CNTN4 and RFTN1 predicted poorer clinical outcomes for LUAD patients. CONCLUSION: Our findings comprehensively analyzed genomics, epigenomics, and transcriptomics of LUAD, offering novel underlying molecular mechanisms for LUAD. Two multi-omics-based core genes (CNTN4 and RFTN1) could become potential therapeutic targets for LUAD.
Entities:
Keywords:
Copy number variation; Lung adenocarcinoma; Methylation; Multi-omics; Prognosis; Subtype
Authors: Zhaoxi Wang; Yongyue Wei; Ruyang Zhang; Li Su; Stephanie M Gogarten; Geoffrey Liu; Paul Brennan; John K Field; James D McKay; Jolanta Lissowska; Beata Swiatkowska; Vladimir Janout; Ciprian Bolca; Milica Kontic; Ghislaine Scelo; David Zaridze; Cathy C Laurie; Kimberly F Doheny; Elizabeth K Pugh; Beth A Marosy; Kurt N Hetrick; Xiangjun Xiao; Claudio Pikielny; Rayjean J Hung; Christopher I Amos; Xihong Lin; David C Christiani Journal: EBioMedicine Date: 2018-05-31 Impact factor: 8.143
Authors: Xiaoshun Shi; Ruidong Li; Xiaoying Dong; Allen Menglin Chen; Xiguang Liu; Di Lu; Siyang Feng; He Wang; Kaican Cai Journal: J Transl Med Date: 2020-02-04 Impact factor: 5.531
Authors: Saioa López; Emilia L Lim; Stuart Horswell; Kerstin Haase; Ariana Huebner; Michelle Dietzen; Thanos P Mourikis; Thomas B K Watkins; Andrew Rowan; Sally M Dewhurst; Nicolai J Birkbak; Gareth A Wilson; Peter Van Loo; Mariam Jamal-Hanjani; Charles Swanton; Nicholas McGranahan Journal: Nat Genet Date: 2020-03-05 Impact factor: 38.330
Authors: Xinjia Ruan; Yuqing Ye; Wenxuan Cheng; Li Xu; Mengjia Huang; Yi Chen; Junkai Zhu; Xiaofan Lu; Fangrong Yan Journal: Front Med (Lausanne) Date: 2022-06-03